Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Plans IPO

NEW YORK (GenomeWeb) – Quanterix said today that it plans to offer more than 3.3 million shares of its common stock at between $14 and $16 per share, as part of an initial public offering.

The Lexington, Massachusetts-based company plans to list its shares on the Nasdaq under the ticker symbol QTRX.

Quanterix intends to use the proceeds to expand its commercial operations and support and grow its existing technology. It plans to launch additional assays for its single-molecule technology Simoa and support the launch of its new instrument, Quanterix SR-X, which it launched in August. In addition, the firm will pursue regulatory clearances and approvals for its instruments and assays in order to potentially launch laboratory developed tests and in vitro diagnostics tests. Quanterix said it may also move into a larger corporate headquarters.

JP Morgan Securities, Leerink Partners, and Cowen and Company will serve as joint book-running managers, while BTIG and Evercore Group will serve as co-managers.

The company also completed an $8.5 million private placement in August and raised $46 million in a Series D financing round in March in order to develop new instruments and expand its assay menu.